ISA27 induces the stabilisation of p53 protein levels by decreasing the interaction of p53 with MDM2 in GBM cells. by Barbara Costa (447711)

Enhanced Nrf2 activity decreases fatty acid transport and results in increased fatty acids content in white adipose tissue. by Jialin Xu (40952)

Decreased expression of the γ-glutamylcysteine ligase and increased hepatic oxidant generation and protein oxidative damage at Day+4 in Allo BMT. by Jung H. Suh (523844)

Blockade of kinin B₁R in the chronic disease phase decreased the clinical symptoms and neuroinflammation in the EAE model. by Rafael C. Dutra (205755)

Impaired glucose metabolism and decreased insulin sensitivity in isolated adipocytes of Nscl-2−/−, Nscl-2−/−×ob/ob mice and controls. by Karen Ruschke (372824)

<i>ogt-1; eel-1 +</i> Pan-neuronal OGT-1 have decreased sensitivity to electroshock and improved locomotion. by Nirthieca Suthakaran (11731101)

“…<p>Shown are each genotype ran through the electroconvulsive seizure assay for 3 seconds at 47V in saline control group. (A) Average time of recovery was significantly decreased in <i>ogt-1; eel-1</i> + Pan-neuronal OGT-1 worms, <i>Ogt-1(ok430) III; eel-1(bgg1) IV; bggSi2[Prab-3</i>::<i>ogt-1a] II</i> (n = 33), in comparison to <i>ogt-1;eel-1</i> double mutants (n = 30) but not significantly different from <i>eel-1</i> null mutants (n = 26). …”

Amino acids 605 and 606 of the PB2 ‘627’ domain are involved in interaction with NP. by Ho-Pan Hsia (4768638)

<i>Cin85</i>-Deficiency results in defective clearance of LCMV-c13 and is correlated with decreased neutralizing antibody titer. by Saravanan Raju (5181014)

Decreased Autophagy in Rat Heart Induced by Anti-β1-Adrenergic Receptor Autoantibodies Contributes to the Decline in Mitochondrial Membrane Potential by Li Wang (15202)

“…Male adult rats were randomized to receive a vehicle or peptide corresponding to the second extracellular loop of the β₁ adrenergic receptor (β₁-AAB group, 0.4 μg/g every two weeks for 12 weeks) and treated with rapamycin (RAPA, an autophagy agonist) at 5 mg/kg/day for two days before detection. …”

Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…Progression-free survival (PFS) and overall survival (OS) were evaluated by a Kaplan-Meier analysis and log-rank test. A Cox regression model was performed to identify independent prognostic factors.…”

Lack of Brain Insulin Receptor Substrate-1 Causes Growth Retardation, with Decreased Expression of Growth Hormone-Releasing Hormone in the Hypothalamus by Takanori Hayashi (5185250)

Substitutions of amino acids 605 and 606 in PB2 affect RNP activity in an NP-dependent manner. by Ho-Pan Hsia (4768638)

The Response of <em>Thalassiosira pseudonana</em> to Long-Term Exposure to Increased CO₂ and Decreased pH by Katharine J. Crawfurd (198710)

The 11R-VIVIT peptide inhibitor of NFATs decreases bacterial phagocytic killing capacity by neutrophils and increases renal susceptibility to UPEC. by Emilie Tourneur (278826)

WNT3 decreases the GCP proliferation marker <i>Atoh1</i> and increases the GCP differentiation marker PAX6. by Sandrine L. Anne (489755)

“…<p>(<i>A</i>) WNT3 decreased <i>Atoh1</i> mRNA levels after 6 h of treatment (Con=1; WNT3: <i>Atoh1</i>=0.52±0.06). …”

Number and percentage of adverse drug reaction reports associated with PREPARE drugs that have a pharmacogneomic indication for the gene SLCO1B1 stratified by decade. by Emma F. Magavern (20947928)

Number and percentage of adverse drug reaction reports associated with PREPARE drugs that have a pharmacogneomic indication for the gene CYP2C19 stratified by decade. by Emma F. Magavern (20947928)

Number and percentage of adverse drug reaction reports associated with PREPARE drugs that have a pharmacogneomic indication for the gene CYP2D6 stratified by decade. by Emma F. Magavern (20947928)

Image_2_Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease.JPEG by Meijuan Liu (4924417)

“…At the cutoff value of 7.955 μg/mL serum ZAG, the sensitivity and specificity for differentiating patients with PCAD from controls were 50.5 and 78.0%, respectively. The combination of ZAG with other clinical variables including age, gender, BMI, SBP, FBG, TC, HDL-C, Cr, and Urea had significantly improved the diagnosis accuracy with a sensitivity of 82.6%, a specificity of 95.0%, and AUC of 0.957 (95% CI, 0.940–0.975, p < 0.05).…”

Image_1_Serum Zinc-α2-Glycoprotein Levels Were Decreased in Patients With Premature Coronary Artery Disease.JPEG by Meijuan Liu (4924417)

“…At the cutoff value of 7.955 μg/mL serum ZAG, the sensitivity and specificity for differentiating patients with PCAD from controls were 50.5 and 78.0%, respectively. The combination of ZAG with other clinical variables including age, gender, BMI, SBP, FBG, TC, HDL-C, Cr, and Urea had significantly improved the diagnosis accuracy with a sensitivity of 82.6%, a specificity of 95.0%, and AUC of 0.957 (95% CI, 0.940–0.975, p < 0.05).…”